Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
Date:5/13/2008

months ended

March 31,

2008 2007

Revenue $ 2,046 $ 2,463

Operating expenses:

Research and development 5,260 5,177

General and administrative 1,448 1,395

Total operating expenses 6,708 6,572

Loss from operations (4,662) (4,109)

Other income (expense)

Interest income 217 608

Interest expense (147) (238)

Other income (expense), net 699 458

Total other income 769 828

Net loss $ (3,893) $ (3,281)

Basic and diluted net loss per share $ (0.25) $ (0.21)

Weighted average shares used in the

computation of basic and diluted net loss

per share 15,739,646 15,688,079


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...Renowned oncology researcher Dr. Daniel Von Hoff, ...Advisory Board, provides an in-depth look at "... trial design that creates rapid accrual rates, su...ings, enthusiasm from investigators and patients, ...nterview is available for download from Medelis, a...
(Date:7/9/2008)...9 /PRNewswire/ -- Tricom Document Management,(Tric...gement of legacy and,current documents for a globa...fic Data Centers, Inc. (PDC), a data processing bu...ents so that they can better focus on their,core c...he latest technological advances and,state-of-the-...
(Date:7/9/2008)...f uKarma,s vertical integration strategy and will,...lth and wellness brands, LOS ANGELES, July 9 /PRN...etin Board: UKMA), a lifestyle multimedia and cons...and personal development, announced today the,firs...a in October, 2008., Xflowsion, with its revoluti...
(Date:7/9/2008)...Contributing Editor, Judy Bachrach Launches Newly,... Terminally Ill and Those ...wire/ -- (ZealousPR) -- Today, http://www.thechec...n for,the terminally ill and those who are close t...new easily accessible FORUM for readers to discuss...
Breaking Medicine News(10 mins):Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 3Health News:Tricom Document Management Expands Onshore Services with Acquisition of Pacific Data Centers, Inc. 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2Health News:Online Advice Column Receives Critical Acclaim; Baby Boomers Found Resourceful During Crisis 2
...experts have revealed that female foeticide is inc... mobile population of India. // The educated peopl...th, and poverty is not the only reason for these s...f selective abortions being made illegal in the co...
...hers belonging to the Yale School of Medicine have...regnant women are concerned can be diagnosed throu...ion in amniotic fluid. The chances of a premature ...ed through this process, according to the research...
... we know about the connection between age factor a...have found new proof that might establish this con...ng a study of baboons, it was discovered that as t...ncreased presence of old cells. It is well known t...
... from Pennsylvania school of medicine have found t...of severe stenosis or narrowed arteries in head ar.../ The result of the study conducted by Professor S...lished in the Journal Circulation. This new diag...
Other Medicine News:Health News:Link between Old Cells and Ageing probed 2
(Date:7/9/2008)... Research Has Set National Safety Standards, ...swire-USNewswire/ -- In a congressional,hearing Se...discussed the,safety and importance of the researc...Affairs (VA) as well as an absolute commitment to ...single veteran would feel improperly,treated or mi...
(Date:7/9/2008)... SAN DIEGO, July 9 /- ... announced positive results from a multiple-ascend...uate the compound,s safety,pharmacokinetics and p...overed oral drug candidate intended for the treatm...tions., The Phase 1b trial was a randomized, doub...
(Date:7/8/2008)... MAIDENHEAD, England, July 8 /PRNewswire-Firs...ldren Against the Leading,Vaccine-Preventable Caus...countries of Cyprus, Hungary, the Kingdom of,Bahra...n for announcing,their decisions to routinely immu...al disease by adding PREVENAR(TM) PCV7 (Pneumococc...
(Date:7/8/2008)... GLP-1 Has Potential to Treat Type 2 Diabetes U... Technology, CEDAR KNOLLS, N.J., July 8 /PR.... (Nasdaq: EMIS ) today announced findings from a...-1 peptide safely and effectively.,The study used ...Eligen(R),technology, and was conducted at Univers...
Breaking Medicine Technology:Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 2Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 3Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 4Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis 5Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules 2Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules 3Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Benchmarking Study Report on Sales Performance Management 21730 1Benchmarking Study Report on Sales Performance Management 21730 2Consumers Urged to Avoid Raw Milk and Raw Milk Products 21727 1Derma Sciences CEO ED Quilty Discusses Company on BNN 21725 1Derma Sciences CEO ED Quilty Discusses Company on BNN 21725 2Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 1Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 2Abbott Opens New State of the Art R 26D Facility to Help Bring Medicines to Patients Faster 21722 3
...tudy evaluating a clinically relevant model of,nor...gent capable,of abrogating the cytotoxic effect of...d OPTISOME(tm) agent was generally well,tolerated ...ent,profile similar to conventional vincristine , ...EWSWIRE) --,Hana Biosciences (Nasdaq:HNAB), a biop...
..., NJ – June 4, 2007 – Genta,Incorporat...sults,from a Phase 2 clinical trial of its markete..., plus rituximab (Rituxan®;,Genentech/IDEC) an...ctory non-Hodgkin’s lymphoma (NHL). The data...can Society of Clinical,Oncology (ASCO) in Chicago...
Other Medicine Technology:Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5
The Snellen chart remains to most popular chart design among clinicians. A range of different optotypes can be displayed in snellen format including British, sheridan-gardner, landolt Cs, tumbling Es
The PacScan 300AP is a portable, combination A-scan and pachymeter which provides easy-to-use touch screen operation. The combination of a high frequency, low noise probes and fast precise algorithms
Lightweight portable pachymeter, with compact LCD screen and optional printer. The Micropach 200P+ is extremely portable, weighing slightly more than 2 lbs (1 kg). The digital pachymeter provides a
16 segment Horizontal Prism bar provides 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 45 PD. 4446 xx Horizontal Prism Bar.
Medicine Products: